The Indian pharmaceutical industry has historically manufactured low-cost drugs for the global poor. Activist mobilizations at the height of the HIV/AIDS epidemic revealed a vast cost gap between global brands and Indian generics, much to the embarrassment of Euro-American corporations that were in the habit of pricing drugs for only the wealthy or well insured. As new drug access controversies focus on anticancer therapies, they reveal new flows of international capital, emergent genetic technologies, and increasingly coercive trade regimes. Together these favor multinational corporate oligopolies, which imperil the legacy of HIV/AIDS activism and the future availability of essential life-saving drugs for the work of global public health. In this essay, I describe how the future of the right to drug access rests uneasily, and potentially calamitously, on a shifting balance of power between global south interests and Euro-American pharmaceutical capital.
Drawing on field research principally from contexts of medical blood donation in North India, this article describes how gifts that are given often critique—by obviation—those that remain ungiven: the care not provided by the Indian state for Bhopal survivors, the family members unwilling to donate blood for their transfusion-requiring relative, and so on. In this way, giving can come to look like a form of criticism. The critiques that acts of giving stage are of absences and deficits: we present cases where large paper hearts donated by survivors of the 1984 Bhopal Gas Disaster to the prime minister of India signal his lack of one, where donated human blood critiques others' unwillingness to do so, where acts of blood donation critique and protest communal violence, and where similar acts of giving over simultaneously highlight a deficit in familial affects and an attempt to resuscitate damaged relational forms. We thus illustrate how critique can operate philanthropically by way of partonomic relations between the given and not-given.
This analysis lays a framework for greater collaboration between the cancer community and social scientists in both research and policy. We argue that the growing cancer burden that low- and middle-income countries face is raising social, political, and economic challenges of global cancer that require interdisciplinary research beyond the traditional biomedical-clinical nexus. First, we briefly review some of the most important existing social science studies that have addressed cancer in low- and middle-income countries, including the main methods, approaches, and findings of this research. Second, we give an overview of recent interdisciplinary collaborations between social scientists and oncologists and demonstrate how qualitative research can help us to understand the distinct challenges of cancer care in low- and middle-income settings. Finally, we identify key areas for future collaboration and suggest possible paths forward for cancer research and policy that involve social science.
Since the 1980s, anthropologists have criticized a US‐centric view of bioethics that presents individual autonomy as a universal principle without acknowledging its embeddedness in time and place. A recent turn in this critique points out how this view has gained dominance across the world, traveling alongside clinical trials and global health interventions. Here, centering a competing bioethical vision disrupts this division between the Global North as a site of ethical conceptualization and the South as the recipient of its diffusion. Indian legal bioethics—concerned with protecting the critically ill body in intensive care—rejects the primacy of autonomy, instead empowering courts to override the choices of patients, families, and doctors. This competing bioethics commits its own harms, misrepresenting vulnerability as a problem of sociomoral underdevelopment rather than as the outcome of increasing inflows of global capital, new patterns of land acquisition, and a growing public‐private health care divide. [bioethics, end of life, norms, ethics, medicine, law, intensive care, Delhi, India]
In 2008, survivors of the 1984 Bhopal Gas Disaster in India undertook a 500-mile march to New Delhi, protesting a long history of governmental neglect of the survivors of the event. This is one episode of a 25-year-old organized international campaign that continues in the present. This article examines the ways in which three bodily substances – blood, hearts and ketones – were produced and circulated through the 2008 protests. Placed within a broader history of substance-politics in the region, this article suggests that these protests produced an imagination of bodily substances that surfaced messy contradictions that became difficult for the Indian State to disregard. This article also shows how these protests distanced themselves from the cynicism attached to similar modes of corporeal activism in the contemporary Indian landscape. In sum, this article traces the production of an activist corporeal counter-discourse that, for at least a time, contaminated the procedures through which the Indian State disregards the health of its marginal citizens.